Metformina Adair

Metformin Hydrochloride, the active ingredient in Metformina Adair, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. GNH USA supplies Metformina Adair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Adair is a biguanide indicated for disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes. - Gestational diabetes (when diet alone is insufficient): assists in achieving target glucose levels during pregnancy.

Metformina Adair may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes or hepatic failure. - Skin reactions: rash or hypersensitivity including Stevens‑Johnson syndrome.

Metformina Adair requires careful monitoring and patient education. - Renal function: assess eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Pregnancy: discuss potential benefits and risks with a healthcare professional. - Monitoring: regularly check HbA1c and vitamin B12 levels during long‑term therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Adair can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal failure and increase lactic acidosis risk. - Cimetidine: can raise plasma metformin concentrations. - Alcohol intoxication: heightens risk of lactic acidosis. - Nephrotoxic drugs (e.g., aminoglycosides): exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can attenuate glucose‑lowering effect. - ACE inhibitors or ARBs: monitor renal function and potassium levels.